Study On Anticancer Effect Of Total Alkaloids (Metaling AF-7) Of Sophora flavescens

Author

Xtshui Yu and Youzhi Wang, Heilongjiang Institute of Pharmaceutical Industry Harbin China Postcode 150040

Proceeding

Trends in Traditional Medicine Research, Proceedings of the International Conference on the Use of Traditional Medicine & Other Natural Products in Health Care

Date

8/6/1993

Keyword

Sophora flavescens, alkaloids, anti-cancer, traditional medicine.

Abstract

In vivo anticancer experiments have proven that intraperitoneal injections of the total alkaloids (Mateling AF-7) from Sophora flavescens at 40 mg, 20 mg and 10 mg produced inhibitory effects on S-180 (solid), EAC (solid) and Lewis lung cancers and exhibited dose-dependent relationship. Among them, at 40 mg/kg, the cancer inhibiting rate was over 40%, some were up to 54%. It has obvious inhibiting action on the model of inducing proventriculus proliferation canceration of mouse with the ethyl sarcosine nitrosamine by inner synthetic method. Its inhibiting rate was over 56%. It was significantly higher than that of control group (p<0.001). It has obvious promoting action on the phagocytic function of macrophage. The phagocytic index was 117.63 (p<0.01). Weight of thymus and spleen significantly increased. Thymus cortex increased its thickness and there was obvious hyperplasia of spleen periarterial cells. It has notable curative effect on rabbit's leukopenia induced by X-ray 600  roentgen whole body irradiation. Acute toxicological study showed that its oral, intraperitoneal and intravenous LD50 in mice were 551.7 mg/kg, 255 mg/kg and 131.9 mg/kg respectively. Subacute toxicity test showed it has no influence on rat's liver function, renal function and hemogram. Pathological section showed no injury to important organs such as heart, liver, kidney, etc. Its MTD for unanesthetised rabbit was 252.6-255.3 mg/kg. Clinical study indicated that the effective rate (CR + PR) was 29.89%. Among them are 50% effective rate for esophagus carcinoma, 37.5% for breast cancer, 50% for cervical carcinoma, 33.3% for intestinal cancer, 23.8% for stomach cancer, 22.2% for oophoroma and 22.5% for lung cancer. Compared with UFT there was no significant difference (p>0.05). In clinical practice, only few patients exhibited slight side effects such as feeling sick, abdominal distension, dizziness, headache, etc.  However, they persisted treatment.